Ajovy for Management of Chronic Migraines
Dr Sana Ghafoor lectures on the novel therapy Ajovy for treatment of chronic migraines. She will be presenting on January 14th 2019 to colleagues in Pennsylvania and New York region. Ajovy has been studied in both episodic and chronic migraines its one of the three CGRP injectables currently on the market for headache management. She will be discussing both clinical trials EM-HALO and CM-HALO during her discussion.
Ajovy is a trade mark of Teva Pharmaceuticals. Teva is an international pharmaceutical company headquartered in Israel. It specializes primarily in generic drugs but has expanded into proprietary pharmaceuticals. It is the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide.